|
Databases, Nucleic Acid
|
L01.313.500.750.300.188.400.325.630 |
|
|
Presenilin-1
|
D12.776.543.696.500 |
|
|
Presenilins
|
D12.776.543.696 |
|
|
Urinary Bladder, Neurogenic
|
C13.351.968.829.760 |
|
|
Sinorhizobium
|
B03.660.050.662.835 |
|
|
Cyclization
|
G02.607.133 |
|
|
Acidosis, Renal Tubular
|
C16.320.831.093 |
|
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11
|
D08.811.277.352.650.775.300.800 |
|
|
Click Chemistry
|
J01.897.836.249.124 |
|
|
Culdoscopy
|
E04.950.300.259 |
|
|
Vaccinium myrtillus
|
B01.650.940.800.575.912.250.341.937.774.875 |
|
|
Salmeterol Xinafoate
|
D000068299 |
[A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
] |
|
Ethics Consultation
|
N05.350.250.200 |
|
|
Fossil Fuels
|
D20.345 |
|
|
Autophagy-Related Protein-1 Homolog
|
D12.776.094.438 |
|
|
beta-Lipotropin
|
D06.472.699.631.525.600.480 |
|
|
Budesonide, Formoterol Fumarate Drug Combination
|
D04.210.500.745.745.654.105.500 |
|
|
Risedronic Acid
|
D000068296 |
[A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
] |
|
Fluticasone-Salmeterol Drug Combination
|
D000068297 |
[A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
, A metered dose inhaler formulation of fluticasone-salmeterol drug combination.
, A dry powdered inhaler formulation of fluticasone-salmeterol drug combination.
] |
|
Fluticasone
|
D000068298 |
[A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.
] |
